For the quarter ending 2025-09-30, BHICD had $476,906 increase in cash & cash equivalents over the period.
| Cash Flow | 2025-09-30 |
|---|---|
| Net income (loss) | 875,720 |
| Accounts receivable | -37,073 |
| Inventory | 699,181 |
| Deferred revenue | 86,662 |
| Accrued services | 693 |
| Accounts payable | 1,939 |
| Prepaid expenses | 30,032 |
| Net cash provided by (used in) operating activities | 272,874 |
| Purchase of intangible assets | 46,064 |
| Advances from related parties | 2,422,096 |
| Repayment to related parties | 2,172,000 |
| Proceeds from the sale of common stock | 0 |
| Net cash provided by financing activities | 250,096 |
| Net increase in cash | 476,906 |
| Cash and cash equivalents at beginning of period | 662,517 |
| Cash and cash equivalents at end of period | 1,139,423 |
BioScience Health Innovations, Inc. (BHICD)
BioScience Health Innovations, Inc. (BHICD)